Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01979523 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 3 | Aug 6, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 |
| clinicaltrials |
| NCT02965703 | Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03419234 | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | active not recruiting | Phase 2 | 223 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT03463460 | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | active not recruiting | Phase 2 | 9 | Dwight OwenOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03862430 | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM(RESTORE) | active not recruiting | Phase 2 | 87 | NuvOx LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05535244 | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma(CAMMA 2) | active not recruiting | Phase 1 / Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 8 | Aug 6, 2026 | clinicaltrials |
| NCT05546866 | Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm | active not recruiting | Phase 2 | 51 | AstraZenecaINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | active not recruiting | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05868265 | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06056895 | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma(TRICK-MCC) | active not recruiting | Phase 2 | 12 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06168812 | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | active not recruiting | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06444880 | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06456463 | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy(TRILLIUM) | active not recruiting | Phase 2 | 85 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT02502786 | Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma | active not recruiting | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT03346135 | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | active not recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03999710 | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04356729 | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 30 | F. Stephen Hodi, MDOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04502407 | Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 40 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05256537 | Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil(OmitMMF) | active not recruiting | Phase 2 | 60 | Ronald PaquetteOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT01386385 | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02143414 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | active not recruiting | Phase 2 | 124 | Acerta Pharma BVINDUSTRY | 10 | Aug 4, 2026 | clinicaltrials |
| NCT03085147 | A Dye for the Detection of Cancer of the Tongue and Mouth | active not recruiting | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03698019 | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | active not recruiting | Phase 2 | 313 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer(BEGONIA) | active not recruiting | Phase 1 / Phase 2 | 243 | AstraZenecaINDUSTRY | 6 | Aug 4, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | active not recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06969027 | JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC | active not recruiting | Phase 2 | 69 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03878095 | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02888743 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT02893917 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02905591 | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC(XACT-LUNG) | active not recruiting | Phase 2 | 43 | Joseph J. Cullen, MD, FACSOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03047213 | Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03237780 | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | active not recruiting | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03517969 | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | active not recruiting | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03854474 | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies(ELM-2) | active not recruiting | Phase 2 | 515 | Regeneron PharmaceuticalsINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT03896503 | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | active not recruiting | Phase 2 | 104 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2026source: clinicaltrials